Sims Limited Achieves Climate Leaders Asia-Pacific 2023 Recognition
27.5.2023 05:49:00 EEST | Business Wire | Press release
Sims Limited (ASX: SGM), a global leader in sustainability and an enabler of the circular economy, has been named to the Financial Times 2023 Asia-Pacific Climate Leaders list for the second time. Sims Limited was one of 275 companies on the prestigious list, which highlights companies that have made genuine greenhouse gas emissions reductions relative to their revenues over a five-year period.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005346/en/
FT-Statista Climate Leaders 2023 logo (Graphic: Business Wire)
For the second consecutive year, Financial Times and Statista examined publicly available disclosures of more than 2,000 companies in the Asia-Pacific region to compile the Climate Leaders Asia-Pacific list. The list is comprised of companies that achieved the greatest reduction in their core emissions intensity between 2016 and 2021 – that is, their Scope 1 and 2 greenhouse gas emissions in relation to revenue – and made further climate-related commitments (such as CDP disclosure scores and transparency on Scope 3 emissions).
“As a company whose purpose is to create a world without waste to preserve our planet, it is humbling to be recognised for our climate achievements and efforts to reduce emissions within our operations,” said Alistair Field, chief executive officer and managing director at Sims Limited. “We truly believe that strong climate action is essential to creating the world we all want to live in and leave for future generations, so we take our role in this process very seriously.”
Moving toward renewable electricity is a critical component of Sims Limited’s decarbonisation plans, and this past year, the company accelerated its carbon neutrality target by 12 years, demonstrating their commitment to decarbonising their own operations. In 2023, Sims Limited’s North America businesses joined their businesses in the United Kingdom, New Zealand, India, and Europe in supporting 100 percent renewable electricity.
The company, which is a signatory of the Global Agreement on Climate Policy Engagement, also ranked 14th on the 2023 Corporate Knights Global 100 List of the World’s Most Sustainable Companies and placed in the top 100 of the As You Sow 2023 Carbon Clean200 list.
Sims Limited’s Sustainability Report contains more information on the company’s decarbonisation efforts and achievements and the social, environmental, and economic value it creates. For a full accounting of the 2023 Climate Asia-Pacific List, visit https://www.ft.com/reports/asia-pacific-climate-leaders.
About Sims Limited
Founded in 1917, Sims Limited is a global leader in sustainability and an enabler of the circular economy that employs almost 5,000 employees who operate from more than 200 facilities across 15 countries. The company’s purpose, create a world without waste to preserve our planet, is what drives us to constantly innovate and offer new solutions in the circular economy for consumers, businesses, governments, and communities around the world. For more information, visit www.simsltd.com.
About Financial Times Climate Leaders Asia-Pacific List
The Financial Times Climate Leaders Asia-Pacific list was published for the first time in 2022. The research was conducted by Statista, an independent consultancy, who reviewed reported emissions data for over 2,000 companies that are headquartered in the Asia-Pacific region. To be featured on the list, companies needed to have made reductions on scope 1 and 2 emissions between 2015 and 2020, relative to revenue.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230526005346/en/
Contact information
Investor Relations
Ana Metelo
Director, Investor Relations
ana.metelo@simsmm.com
Media Relations
Réal Hamilton-Romeo
Global Head, Communications and Marketing
real.hamiltonromeo@simsmm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
